Skip to main content
. Author manuscript; available in PMC: 2024 Aug 14.
Published in final edited form as: Pharmacotherapy. 2017 Nov 27;37(12):1489–1497. doi: 10.1002/phar.2049

Figure 2.

Figure 2.

Per patient cost of Clostridium difficile–associated diarrhea (CDAD) treatment in the general population for two different treatment pathways (fidaxomicin first line vs vancomycin first line), by CDAD episode. FDX = fidaxomicin; rCDAD = recurrent C. difficile–associated diarrhea; VAN = vancomycin.